Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Twelve analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […]
Related Keywords
William Blair , Sujal Shah , Piper Sandler , Charles Mcwherter , Cymabay Therapeutics Inc , Securities Exchange Commission , Vanguard Group Inc , Nasdaq , Tudor Investment Corp Et Al , Manufacturers Life Insurance Company , Cymabay Therapeutics , Get Free Report , Exchange Commission , Bay Capital Management , Bay Therapeutics , Get Free , Cymabay Therapeutics Daily , Nasdaq Cbay , Cbay , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.